Net sales more than doubled in 2024 with improved gross margin and narrowed losses. Strategic focus shifted to neurosurgery, supported by clinical and regulatory milestones and SEK 22.4 million in new financing.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.